Deepankar Chakroborty
MSc
Epidermal Growth Factor Receptor (EGFR), EGFR family; Receptor Tyrosine Kinases; Tyrosine Kinase inhibitors; Cancer; Cancer Biology; Bioinformatics; Functional Genomics; R statistical programming; Therapeutic resistance; High -throughput screen
I am a Doctoral student in the Turku Doctoral Programme of Molecular Medicine. I have a background in biotechnology and bioinformatics. Currently, I am pursuing my PhD under the joint supervision of Prof. Klaus Elenius and Dr. Laura Elo.
Efforts of functional characterization of cancer-associated somatic mutations in oncogenes have been largely incomprehensive because they do not encompass the large majority. I have developed a pipeline to analyze thousands of variants of an oncogenic kinase gene in a single assay, I call iSCREAM (in vitro SCReen for Activating Mutation). We are developing the iSCREAM workflow to preemptively identify and characterize on-target secondary mutations that can cause therapeutic resistance, and then subsequently identify therapies that would potentially work for those resistant mutations.
- Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target (2018)
- BMC Cardiovascular Disorders
- Transcriptional Repressor HIC1 Contributes to Suppressive Function of Human Induced Regulatory T Cells (2018)
- Cell Reports
- The L1TD1 Protein Interactome Reveals the Importance of Post-transcriptional Regulation in Human Pluripotency (2015)
- Stem Cell Reports
- Gene expression analysis in cancer microarray datasets, investigating the role of an Embryonic Stem Cell Factor in prognosis (2014) Chakroborty Deepankar



